agios pharmaceuticals inc. - AGIO
AGIO
Close Chg Chg %
28.42 -0.04 -0.14%
Open Market
28.38
-0.04 (0.14%)
Volume: 51.13K
Last Updated:
May 13, 2026, 10:12 AM EDT
Company Overview: agios pharmaceuticals inc. - AGIO
AGIO Key Data
| Open $28.21 | Day Range 28.08 - 28.70 |
| 52 Week Range 22.24 - 45.99 | Market Cap $1.66B |
| Shares Outstanding 59.47M | Public Float 54.41M |
| Beta 0.58 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$7.25 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.28M |
AGIO Performance
| 1 Week | 2.27% | ||
| 1 Month | -13.67% | ||
| 3 Months | 1.65% | ||
| 1 Year | -2.60% | ||
| 5 Years | -48.53% |
AGIO Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
10
Full Ratings ➔
About agios pharmaceuticals inc. - AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
AGIO At a Glance
Agios Pharmaceuticals, Inc.
88 Sidney Street
Cambridge, Massachusetts 02139-4169
| Phone | 1-617-649-8600 | Revenue | 54.03M | |
| Industry | Pharmaceuticals: Major | Net Income | -412,781,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 48.03% | |
| Fiscal Year-end | 12 / 2026 | Employees | 540 | |
| View SEC Filings |
AGIO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 29.207 |
| Price to Book Ratio | 1.333 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.636 |
| Enterprise Value to Sales | 14.137 |
| Total Debt to Enterprise Value | 0.053 |
AGIO Efficiency
| Revenue/Employee | 100,051.852 |
| Income Per Employee | -764,409.259 |
| Receivables Turnover | 5.108 |
| Total Asset Turnover | 0.037 |
AGIO Liquidity
| Current Ratio | 11.46 |
| Quick Ratio | 11.059 |
| Cash Ratio | 10.394 |
AGIO Profitability
| Gross Margin | 78.674 |
| Operating Margin | -873.865 |
| Pretax Margin | -765.894 |
| Net Margin | -764.013 |
| Return on Assets | -27.887 |
| Return on Equity | -30.195 |
| Return on Total Capital | -33.469 |
| Return on Invested Capital | -29.526 |
AGIO Capital Structure
| Total Debt to Total Equity | 3.37 |
| Total Debt to Total Capital | 3.26 |
| Total Debt to Total Assets | 3.099 |
| Long-Term Debt to Equity | 1.828 |
| Long-Term Debt to Total Capital | 1.769 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Agios Pharmaceuticals Inc. - AGIO
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 14.24M | 26.82M | 36.50M | 54.03M | |
Sales Growth
| - | +88.36% | +36.07% | +48.03% | |
Cost of Goods Sold (COGS) incl D&A
| 20.26M | 9.50M | 9.82M | 11.52M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 18.56M | 6.62M | 5.65M | 5.18M | |
Depreciation
| 18.56M | 6.62M | 5.65M | 5.18M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +7.91% | -53.10% | +3.30% | +17.36% | |
Gross Income
| (6.02M) | 17.32M | 26.68M | 42.51M | |
Gross Income Growth
| +67.92% | +387.55% | +54.05% | +59.32% | |
Gross Profit Margin
| -42.30% | +64.57% | +73.10% | +78.67% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 383.02M | 408.81M | 452.42M | 514.64M | |
Research & Development
| 271.35M | 288.90M | 295.63M | 334.36M | |
Other SG&A
| 111.68M | 119.90M | 156.78M | 180.28M | |
SGA Growth
| +6.50% | +6.73% | +10.67% | +13.75% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (389.05M) | (391.49M) | (425.74M) | (472.13M) | |
Non Operating Income/Expense
| 157.25M | 39.40M | 1.14B | 58.34M | |
Non-Operating Interest Income
| 12.79M | 33.34M | 48.08M | 56.38M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (231.80M) | (352.09M) | 717.97M | (413.80M) | |
Pretax Income Growth
| +34.98% | -51.89% | +303.92% | -157.63% | |
Pretax Margin
| -1,627.82% | -1,312.63% | +1,967.15% | -765.89% | |
Income Tax
| - | - | 44.24M | (1.02M) | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (231.80M) | (352.09M) | 673.73M | (412.78M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (231.80M) | (352.09M) | 673.73M | (412.78M) | |
Net Income Growth
| +34.98% | -51.89% | +291.35% | -161.27% | |
Net Margin Growth
| -1,627.82% | -1,312.63% | +1,845.92% | -764.01% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (231.80M) | (352.09M) | 673.73M | (412.78M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (231.80M) | (352.09M) | 673.73M | (412.78M) | |
EPS (Basic)
| -4.2308 | -6.3267 | 11.8598 | -7.1204 | |
EPS (Basic) Growth
| +33.47% | -49.54% | +287.46% | -160.04% | |
Basic Shares Outstanding
| 54.79M | 55.65M | 56.81M | 57.97M | |
EPS (Diluted)
| -4.2308 | -6.3267 | 11.6382 | -7.1204 | |
EPS (Diluted) Growth
| +33.47% | -49.54% | +283.95% | -161.18% | |
Diluted Shares Outstanding
| 54.79M | 55.65M | 57.89M | 57.97M | |
EBITDA
| (370.49M) | (384.86M) | (420.08M) | (466.95M) | |
EBITDA Growth
| -3.02% | -3.88% | -9.15% | -11.16% | |
EBITDA Margin
| -2,601.74% | -1,434.83% | -1,150.98% | -864.28% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 41.50 | |
| Number of Ratings | 10 | Current Quarters Estimate | -1.607 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | -6.13 | |
| Last Quarter’s Earnings | -1.69 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -7.12 | Next Fiscal Year Estimate | -4.678 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 10 | 10 | 10 | 10 |
| Mean Estimate | -1.61 | -1.47 | -6.13 | -4.68 |
| High Estimates | -1.48 | -1.31 | -5.50 | -3.80 |
| Low Estimate | -1.69 | -1.60 | -6.64 | -6.16 |
| Coefficient of Variance | -3.99 | -7.50 | -6.80 | -19.11 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 7 | 7 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 3 | 3 | 3 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Agios Pharmaceuticals Inc. - AGIO
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Agios Pharmaceuticals Inc. - AGIO
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 7, 2026 | Krishnan Viswanadhan Chief Corp Dev & Strategy | 8,100 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Krishnan Viswanadhan Chief Corp Dev & Strategy | 10,282 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $34.71 per share | 356,888.22 |
| Apr 7, 2026 | Krishnan Viswanadhan Chief Corp Dev & Strategy | 13,241 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Tsveta Milanova Chief Commercial Officer | 8,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Brian M. Goff Chief Executive Officer; Director | 190,076 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Brian M. Goff Chief Executive Officer; Director | 177,604 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $34.71 per share | 6,164,634.84 |
| Apr 7, 2026 | Brian M. Goff Chief Executive Officer; Director | 191,104 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Brian M. Goff Chief Executive Officer; Director | 184,508 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $34.71 per share | 6,404,272.68 |
| Apr 7, 2026 | Brian M. Goff Chief Executive Officer; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Brian M. Goff Chief Executive Officer; Director | 40,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Tsveta Milanova Chief Commercial Officer | 50,091 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Tsveta Milanova Chief Commercial Officer | 46,829 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $34.71 per share | 1,625,434.59 |
| Mar 6, 2026 | T. J. Washburn Principal Accounting Officer | 868 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $28.88 per share | 25,067.84 |
| Jul 16, 2025 | David T. Scadden Director | 27,707 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 16, 2025 | David T. Scadden Director | 17,603 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $40 per share | 704,120.00 |
| Jul 16, 2025 | David T. Scadden Director | 19,003 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $18.09 per share | 343,764.27 |
| Jul 11, 2025 | Jay T. Backstrom Director | 4,341 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 11, 2025 | Jay T. Backstrom Director | 23,393 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |